New in 2023 !

APLUSA launched a new syndicated study analyzing in post-transplant CMV (for both Solid Organ Transplant – SOT – and Hematopoietic Stem Cell Transplantation – HSCT -), with results expected at the end of March 2023. The study design includes both Awareness, Trial & Usage – ATU – questions and detailed anonymised patient charts.

The study has been designed to provide:

• A market landscape (market penetration, use of diagnostics, level of use of prophylaxis, pre-emptive and curative therapies…)
• Attitude and usage of CMV treatments in hospitals for transplant patients (current protocols in anti-viral treatment – focus R/R CMV viremia, image and awareness including products in development…)
• Management of CMV patients in transplant (patient characteristics, market shares, treatment patterns, patient pathways…)
• Market opportunities (product potential, opportunities for growth…)

Results will be available in the coming months. Would you be interested in receiving more details? We would be happy to set up a short exploratory meeting, or a longer more detailed presentation with one of our experts!